Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP1 | O94782 | 3/20 | 0.35 |
| ▸ | HTR7 | P34969 | 1/20 | 0.32 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.31 |
| ▸ | CCL5 | P13501 | 1/20 | 0.31 |
| ▸ | DRD3 | P35462 | 1/20 | 0.30 |
| ▸ | HTR6 | P50406 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25613560 | 0.89 | USP1 (0.34) | USP1 | |
| SCHEMBL25628845 | 0.88 | USP1 (0.34) | USP1HTR7TMEM97KDM4ETSHR | |
| SCHEMBL25613569 | 0.81 | KDM4E (0.39) | HTR7TMEM97KDM4ETSHRMCL1 | |
| SCHEMBL25478800 | 0.80 | USP1 (0.35) | USP1HTR7TMEM97CCL5 | |
| SCHEMBL24005474 | 0.79 | USP1 (0.35) | USP1 | |
| SCHEMBL25613561 | 0.77 | ALDH1A1 (0.35) | TSHR | |
| SCHEMBL25613559 | 0.77 | CA12 (0.33) | HTR7TMEM97 | |
| SCHEMBL25613568 | 0.76 | MEN1 (0.32) | USP1HTR7TMEM97 | |
| SCHEMBL25628689 | 0.75 | ITGB2 (0.36) | TSHR | |
| SCHEMBL25613665 | 0.74 | USP1 (0.36) | USP1HTR7HTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230159527-A1 | COMPOUNDS AS BCL-2 INHIBITORS | FOCHON BIOSCIENCES, LTD. (CN) | 2023-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159527-A1 | COMPOUNDS AS BCL-2 INHIBITORS | BCL2, BCL2L2, BCL2L1 | USP1 2722/4885HTR7 2953/4885TMEM97 2285/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.